Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Japan Approval Another Boost For Tagrisso in 1L NSCLC

Aug 21 2018

• By Ian Haydock

Digital illustration of Cancer cell in colour background — TAGRISSO FOR 1L NSCLC AMONG LATEST JAPAN APPROVALS • Source: Shutterstock

Related Content

Latest Japan Approvals Include Entyvio, Imfinzi, World-First Indication

Jul 03 2018

New Japan Approvals Include Tafinlar, Tagrisso

Mar 29 2016

Mogamulizumab Nips At Adcetris’s Heels In CTCL After New Results

Apr 12 2017

New EU Approval Further Boost For Tagrisso As Threats Recede

Jun 11 2018

Related Companies

AstraZeneca PLC

Pfizer Inc.

Kyowa Kirin Co., Ltd.

Astellas Pharma, Inc.

Ironwood Pharmaceuticals, Inc.

Additional Topics

Japan Asia Pacific Approvals Commercial Cancer BioPharmaceutical

More from Japan

More from Focus On Asia

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.